chr11-8233861-C-A
Position:
Variant summary
Our verdict is Benign. Variant got -11 ACMG points: 0P and 11B. BP4_ModerateBP6BA1
The NM_002315.3(LMO1):c.26-3357G>T variant causes a intron change. The variant allele was found at a frequency of 0.238 in 152,076 control chromosomes in the GnomAD database, including 5,286 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Benign,protective (no stars).
Frequency
Genomes: 𝑓 0.24 ( 5286 hom., cov: 32)
Consequence
LMO1
NM_002315.3 intron
NM_002315.3 intron
Scores
2
Clinical Significance
Conservation
PhyloP100: 5.03
Genes affected
LMO1 (HGNC:6641): (LIM domain only 1) This locus encodes a transcriptional regulator that contains two cysteine-rich LIM domains but lacks a DNA-binding domain. LIM domains may play a role in protein interactions; thus the encoded protein may regulate transcription by competitively binding to specific DNA-binding transcription factors. Alterations at this locus have been associated with acute lymphoblastic T-cell leukemia. Chromosomal rearrangements have been observed between this locus and at least two loci, the delta subunit of the T-cell antigen receptor gene and the LIM domain binding 1 gene. Alternatively spliced transcript variants have been described. [provided by RefSeq, Jul 2012]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Benign. Variant got -11 ACMG points.
BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.31).
BP6
Variant 11-8233861-C-A is Benign according to our data. Variant chr11-8233861-C-A is described in ClinVar as [Benign, protective]. Clinvar id is 221554.Status of the report is no_assertion_criteria_provided, 0 stars.
BA1
GnomAd4 highest subpopulation (NFE) allele frequency at 95% confidence interval = 0.301 is higher than 0.05.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | UniProt |
---|---|---|---|---|---|---|---|
LMO1 | NM_002315.3 | c.26-3357G>T | intron_variant | ENST00000335790.8 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|
LMO1 | ENST00000335790.8 | c.26-3357G>T | intron_variant | 1 | NM_002315.3 | A1 | |||
LMO1 | ENST00000428101.6 | c.23-3357G>T | intron_variant | 1 | P4 | ||||
LMO1 | ENST00000524379.1 | n.52-3357G>T | intron_variant, non_coding_transcript_variant | 1 | |||||
LMO1 | ENST00000534484.1 | c.-8-3357G>T | intron_variant | 5 |
Frequencies
GnomAD3 genomes AF: 0.238 AC: 36177AN: 151958Hom.: 5286 Cov.: 32
GnomAD3 genomes
AF:
AC:
36177
AN:
151958
Hom.:
Cov.:
32
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
We have no GnomAD4 exomes data on this position. Probably position not covered by the project.
GnomAD4 genome AF: 0.238 AC: 36168AN: 152076Hom.: 5286 Cov.: 32 AF XY: 0.244 AC XY: 18136AN XY: 74324
GnomAD4 genome
AF:
AC:
36168
AN:
152076
Hom.:
Cov.:
32
AF XY:
AC XY:
18136
AN XY:
74324
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
Asia WGS
AF:
AC:
767
AN:
3478
ClinVar
Significance: Benign; protective
Submissions summary: Benign:2
Revision: no assertion criteria provided
LINK: link
Submissions by phenotype
LIM DOMAIN ONLY-1 POLYMORPHISM Benign:1
Benign, no assertion criteria provided | literature only | OMIM | Feb 05, 2016 | - - |
Neuroblastoma, susceptibility to, 7 Benign:1
protective, no assertion criteria provided | literature only | ClinVar Staff, National Center for Biotechnology Information (NCBI) | - | Oldridge et al., 2015 (PubMed 26560027) state that the SNP rs2168101 G>T is the most highly associated variant (combined P = 7.47 × 10(-29), odds ratio 0.65, 95% confidence interval 0.60-0.70), and resides in a super-enhancer defined by extensive acetylation of histone H3 lysine 27 within the first intron of LMO1. The ancestral G allele that is associated with tumour formation resides in a conserved GATA transcription factor binding motif. We show that the newly evolved protective TATA allele is associated with decreased total LMO1 expression (P = 0.028) in neuroblastoma primary tumours, and ablates GATA3 binding." - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
CADD
Uncertain
DANN
Benign
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at